Weighted TOPSIS evaluates rationality of sacubitril valsartan in treatment of chronic heart failure
AIM To analytical hierarchy process(AHP)and technique for order preference by similarity to an ideal solution(TOPSIS)were used to evaluate the rationality of the use of sacubitril valsartan in the treatment of chronic heart failure,to provide a reference for clinical pharmacists to intervene and promote the rational use of clinical drugs.METHODS Based on the drug instruction of sacubitril valsartan,treatment guidelines,expert consensus and relevant literature,the evaluation criteria for the rational use of sacubitril valsartan in the treatment of chronic heart failure was established,and the AHP method was used to assign weights to the indicators and the TOPSIS method was used to evaluate the rational use of sacubitril valsartan in the treatment of chronic heart failure in our hospital records from January 2022 to June 2022.RESULTS The top 5 indicators with higher weight of the established evaluation criteria were 0.277 8 for indications,0.199 6 for prohibited combination,0.176 3 for combination therapy,0.114 0 for dose administration and 0.081 5 for drug conversion.Ninety medical records were included,of which 22 cases(24％)were evaluated as reasonable medication use,50 cases(56％)as basic reasonable medication use and 18 cases(20％)as unreasonable medication use.CONCLUSION The AHP-weighted TOPSIS method can be used to evaluate the rationality of sacubitril valsartan in the treatment of chronic heart failure,which can identify problems in clinical application,provide a basis for pharmacological intervention by clinical pharmacists and promote rational drug use in clinical departments.
万方数据
维普
